Monroe Biomedical Research LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$606,898	90
2024	Research	$316,695	13
2023	Research	$11,112	5
2022	Research	$25,918	11
2021	Research	$78,158	25

Breakdown

Who paid Research payments · program years 2021–2025

Indivior Inc. $525,451 65 payments
Amgen Inc. $312,535 4 payments
Teva Pharmaceuticals USA, Inc. $115,187 41 payments
Genentech, Inc. $47,455 21 payments
GlaxoSmithKline, LLC. $20,849 3 payments
F. Hoffmann-La Roche AG $11,243 6 payments
AbbVie, Inc. $6,060 4 payments

Studies the money was for Research payments · program years 2021–2025

A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of Indv-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder $525,451 65 payments
A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a) $247,453 1 payment
A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study to Assess the Safety, Efficacy and Pharmacodynamics of TEV 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma $55,526 25 payments
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma $41,384 8 payments
UC P3: Double-Blind Treat Straight Through $26,645 14 payments
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease (SIBERITE-1) $25,715 9 payments
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity $25,434 1 payment
A Phase 3A, Observer-Blind, Randomized, Controlled Study to Demonstrat $20,849 3 payments
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy and Living With Overweight or Obesity $20,348 1 payment
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure Therapy and Living With Overweight or Obesity (MARITIME-OSA-2) $19,300 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.